EP1349571A4 - ROTAVIRUS ENTEROTOXIN NSP4 AND METHOD FOR ITS USE - Google Patents

ROTAVIRUS ENTEROTOXIN NSP4 AND METHOD FOR ITS USE

Info

Publication number
EP1349571A4
EP1349571A4 EP01992588A EP01992588A EP1349571A4 EP 1349571 A4 EP1349571 A4 EP 1349571A4 EP 01992588 A EP01992588 A EP 01992588A EP 01992588 A EP01992588 A EP 01992588A EP 1349571 A4 EP1349571 A4 EP 1349571A4
Authority
EP
European Patent Office
Prior art keywords
nsp4
relates
rotavirus
rotavirus enterotoxin
enterotoxin nsp4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01992588A
Other languages
German (de)
French (fr)
Other versions
EP1349571A2 (en
Inventor
Mary K Estes
Judith M Ball
Peng Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/705,621 external-priority patent/US6673355B1/en
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of EP1349571A2 publication Critical patent/EP1349571A2/en
Publication of EP1349571A4 publication Critical patent/EP1349571A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The rotavirus non-structural glycoprotein, NSP4, performs multiple functions in the virus replication cycle, especially during viral morphogenesis. Specifically, NSP4 is an intracellular receptor that mediates the acquisition of a transient membrane envelope during the budding of newly formed subviral particles into the endoplasmic reticulum (ER). The present invention relates to NSP4 and methods of use. More particularly, it relates to the use of NSP4 and fragments thereof (NSP4 114-135, NSP4 120-147, NSP4 112-174, or NSP4 112-150) as a prevention and/or treatment of rotaviral disease.
EP01992588A 2000-11-03 2001-11-02 ROTAVIRUS ENTEROTOXIN NSP4 AND METHOD FOR ITS USE Withdrawn EP1349571A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/705,621 US6673355B1 (en) 1995-06-14 2000-11-03 Rotavirus enterotoxin NSP4 and methods of using same
US705621 2000-11-03
PCT/US2001/045255 WO2002036172A2 (en) 2000-11-03 2001-11-02 Rotavirus enterotoxin nsp4 and methods of using same

Publications (2)

Publication Number Publication Date
EP1349571A2 EP1349571A2 (en) 2003-10-08
EP1349571A4 true EP1349571A4 (en) 2005-02-16

Family

ID=24834264

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01992588A Withdrawn EP1349571A4 (en) 2000-11-03 2001-11-02 ROTAVIRUS ENTEROTOXIN NSP4 AND METHOD FOR ITS USE

Country Status (4)

Country Link
EP (1) EP1349571A4 (en)
AU (1) AU2002220025A1 (en)
CA (1) CA2427809A1 (en)
WO (1) WO2002036172A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1576877A1 (en) * 2004-03-04 2005-09-21 Bioprotein Technologies Preparation of recombinant rotavirus proteins in milk of transgenic non-human mammals
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
ES2632429T3 (en) * 2012-02-14 2017-09-13 Merial, Inc. Subunit rotavirus vaccines and procedures for the manufacture and use thereof
EP2849779B1 (en) 2012-05-16 2021-01-06 Adelaide Research & Innovation Pty Ltd. Cellular vaccine and method of inducing an immune response in a subject
CA2974438A1 (en) * 2015-01-23 2016-07-28 Medicago Inc. Rotavirus-like particle production in plants
CN108504718A (en) * 2018-03-27 2018-09-07 东莞市第三人民医院 A kind of CaSR is in the metainfective expression analysis method of RV, NSP4
CN117866858B (en) * 2023-11-30 2024-06-21 吉林农业大学 Recombinant Lactobacillus plantarum expressing porcine rotavirus antigen and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007941A1 (en) * 1990-10-25 1992-05-14 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
WO2001027335A1 (en) * 1999-10-14 2001-04-19 Baylor College Of Medicine A novel adjuvant
WO2001066566A2 (en) * 2000-03-07 2001-09-13 Institut National De La Recherche Agronomique (Inra) Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186933A (en) * 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
CA2224697A1 (en) * 1995-06-14 1997-01-03 Peng Tian Rotavirus enterotoxin nsp4 and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007941A1 (en) * 1990-10-25 1992-05-14 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
WO2001027335A1 (en) * 1999-10-14 2001-04-19 Baylor College Of Medicine A novel adjuvant
WO2001066566A2 (en) * 2000-03-07 2001-09-13 Institut National De La Recherche Agronomique (Inra) Rotavirus pseudoviral particles and use thereof for vectorizing proteins or nucleic acids

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CRAWFORD S E ET AL: "Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells", JOURNAL OF VIROLOGY 1994 UNITED STATES, vol. 68, no. 9, 1994, pages 5945 - 5952, XP002289212, ISSN: 0022-538X *
See also references of WO0236172A3 *
ZENG C Q-Y ET AL: "IMMUNIZATION OF MICE WITH THE VIRAL ENTEROTOXIN INDUCES HOMOTYPIC AND HETEROTYPIC PROTECTION AGAINST ROTAVIRUS DIARRHEA", GASTROENTEROLOGY, W.B.SAUNDERS COMPANY, PHILADELPHIA, US, vol. 120, no. SUPPL 5, April 2001 (2001-04-01), pages A214, XP009035735, ISSN: 0016-5085 *
ZHANG MINGDONG ET AL: "A functional NSP4 enterotoxin peptide secreted from rotavirus-infected cells", JOURNAL OF VIROLOGY, vol. 74, no. 24, December 2000 (2000-12-01), pages 11663 - 11670, XP002303656, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2002036172A3 (en) 2002-09-19
AU2002220025A1 (en) 2002-05-15
CA2427809A1 (en) 2002-05-10
WO2002036172A2 (en) 2002-05-10
EP1349571A2 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
WO2003077942A3 (en) Virus-like particles of human papillomavirus
WO2004042001A3 (en) Virus-like particles, methods of preparation, and immonogenic compositions
NO20063157L (en) Influenza immunogen and vaccine
CY1108789T1 (en) CLEANING HBV ANTIGENS FOR USE IN VACCINES
WO2002018585A8 (en) Packaging of positive-strand rna virus replicon particles
WO2007109600A3 (en) Extractions and methods comprising elder species
CY1107451T1 (en) Hydrobromic ESCITALOPRAM AND METHOD FOR PREPARING IT
EP1349571A4 (en) ROTAVIRUS ENTEROTOXIN NSP4 AND METHOD FOR ITS USE
WO2002046366A3 (en) Rf2a and rf2b transcription factors
EP1420819A4 (en) SUBUNIT VACCINE FOR INFECTIOUS PANCREATIC NECROSIS VIRUS
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
WO2009075488A3 (en) Anti-influenza viral composition containing bark or stem extract of alnus japonica
WO2003049765A3 (en) Enveloped virus vaccine and method for production
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
WO2001097824A3 (en) Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
WO2006061700A3 (en) Rapid disintegrating taste masked compositions and a process for its preparations
WO2007144569A3 (en) Antiviral astragalus extract
WO2006024240A3 (en) Vaccine composition against hepatitis c virus
WO2005108560A3 (en) Synthesis and purification of west nile virus virus-like particles
AU2003300870A8 (en) Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
MX2007013472A (en) Vaccine.
WO2006039533A3 (en) Bcr-abl imatinib resistance-associated peptides and methods of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030603

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050103

17Q First examination report despatched

Effective date: 20050401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060601